20 results found.

Plaque Psoriasis Clinical Trial using MK-3222 200 mg; MK-3222 100 mg; Matching Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010).
MK-3222 200 mg; MK-3222 100 mg; Matching Placebo

Plaque Psoriasis Clinical Trial using MK-3222 200 mg; MK-3222 100 mg; MK-3222 Placebo; Etanercept Placebo; Etanercept 50 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 9000222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis.
MK-3222 200 mg; MK-3222 100 mg; MK-3222 Placebo; Etanercept Placebo; Etanercept 50 mg

Psoriasis Clinical Trial using Adalimumab (Humirar); ABP 501

Amgen - Recruiting 18 years to 75 years.
- A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis.
Adalimumab (Humirar); ABP 501

Psoriasis Clinical Trial using BI 655066; Ustekinumab

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066).
BI 655066; Ustekinumab

Chronic Plaque-type Psoriasis Clinical Trial using CJM112; Secukinumab; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients.
CJM112; Secukinumab; Placebo

Moderate to Severe Plaque-type Psoriasis Clinical Trial using Secukinumab (AIN457); Placebo

Novartis - Recruiting 18 years or older.
- A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 2 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab.
Secukinumab (AIN457); Placebo

Plaque Psoriasis Clinical Trial using DFD01 Spray; Comp01 Lotion

Promius Pharma, LLC - Recruiting 18 years to 90 years.
- .
DFD01 Spray; Comp01 Lotion

Psoriasis Clinical Trial using etanercept

Amgen - Recruiting 18 years or older.
- Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab.
etanercept

Psoriasis Vulgaris, or Psoriasis Clinical Trial using tofacitinib ointment 20 mg/g; tofacitinib ointment 10 mg/g; placebo ointment (vehicle)

Pfizer - Recruiting 18 years or older.
- A Phase 2b, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.
tofacitinib ointment 20 mg/g; tofacitinib ointment 10 mg/g; placebo ointment (vehicle)

Psoriasis Clinical Trial using CP-690,550

Pfizer - Recruiting 18 years or older.
- A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis.
CP-690,550

Psoriasis Clinical Trial using ASKP1240; Placebo

Astellas Pharma Inc - Recruiting 18 years to 75 years.
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis.
ASKP1240; Placebo

Plaque Type Psoriasis Clinical Trial using GP2017 Adalimumab; Humira r Adalimumab

Sandoz - Recruiting 18 years or older.
- A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humirar in Patients With Moderate to Severe Chronic Plaque-type Psoriasis.
GP2017 Adalimumab; Humira r Adalimumab

Psoriasis Clinical Trial using 80 mg ixekizumab; 50 mg etanercept; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period.
80 mg ixekizumab; 50 mg etanercept; Placebo

Psoriasis Clinical Trial using Brodalumab

Amgen - Recruiting 18 years to 75 years.
- An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis.
Brodalumab

Psoriasis Clinical Trial using Vehicle; M518101

Maruho North America Inc. - Recruiting 18 years or older.
- A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center PhaseIII Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis.
Vehicle; M518101

Psoriasis Clinical Trial using M518101

Maruho North America Inc. - Recruiting 18 years or older.
- An Open-label, Multi-center, Long-term Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis.
M518101

Psoriasis Clinical Trial using Skin biopsy; Blood test

Rockefeller University - Recruiting 18 years to 80 years.
- Comparative Analysis of Small and Large Plaque Psoriasis.
Skin biopsy; Blood test

Psoriasis Clinical Trial using VB-201 80mg; VB-201 160mg; Placebo

Vascular Biogenics Ltd. operating as VBL Therapeutics - Recruiting 18 years to 75 years.
- A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis.
VB-201 80mg; VB-201 160mg; Placebo

Plaque Psoriasis Clinical Trial using Ixekizumab Auto-Injector; Ixekizumab Prefilled Syringe

Eli Lilly and Company - Recruiting 18 years or older.
- Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis.
Ixekizumab Auto-Injector; Ixekizumab Prefilled Syringe

Plaque Psoriasis Clinical Trial using Calcitriol 3 mcg/g ointment

Galderma - Recruiting 2 years to 12 years.
- Pharmacokinetics and Pharmacodynamics of Calcitriol 3 Mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis.
Calcitriol 3 mcg/g ointment